Phathom Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Oct 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 29, 2026
PHAT$5.33+1.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and par value amounts)
| September 30,2026 | December 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $184,558 | $129,972 |
| Prepaid expenses and other current assets | 8,222 | 15,353 |
| Accounts receivable, net | 107,602 | 78,129 |
| Inventory | 7,632 | 5,518 |
| Total current assets | 308,014 | 228,972 |
| Property and equipment, net | 935 | 1,064 |
| Operating lease right-of-use assets | 2,310 | 2,603 |
| Restricted cash | 2,864 | 2,861 |
| Inventory, non-current | 27,331 | 20,732 |
| Other long-term assets | 3,566 | 2,917 |
| Total assets | $345,020 | $259,149 |
| Liabilities and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $11,109 | $4,983 |
| Accrued expenses | 121,147 | 89,831 |
| Accrued interest | 1,453 | 1,833 |
| Operating lease liabilities, current | 673 | 648 |
| Current portion of revenue interest financing liability | 40,520 | 27,249 |
| Other current liabilities | — | 7,500 |
| Total current liabilities | 174,902 | 132,044 |
| Long-term debt, net of discount | 165,540 | 209,087 |
| Revenue interest financing liability | 346,973 | 350,122 |
| Operating lease liabilities | 1,744 | 2,065 |
| Other long-term liabilities | 3,500 | 4,000 |
| Total liabilities | 692,659 | 697,318 |
| Commitments and contingencies (Note 3) | ||
| Stockholders’ deficit: | ||
| Preferred stock, $0.0001 par value; authorized shares — 40,000,000 at September 30, 2026 and December 31, 2025; no shares issued and outstanding at September 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value; authorized shares — 400,000,000 at September 30, 2026 and December 31, 2025; issued and outstanding shares — 81,222,933 and 71,419,025 at September 30, 2026 and December 31, 2025, respectively | 8 | 6 |
| Treasury stock — 19 shares at September 30, 2026 and December 31, 2025 | — | — |
| Additional paid-in capital | 1,198,459 | 1,046,083 |
| Accumulated deficit | (1,546,106) | (1,484,258) |
| Total stockholders’ deficit | (347,639) | (438,169) |
| Total liabilities and stockholders’ deficit | $345,020 | $259,149 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.